New Pill-and-Shot combo aims to wipe out HER2+ breast cancer before surgery

NCT ID NCT07095023

Recruiting now Disease control Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking an oral chemotherapy (paclitaxel) along with a fixed-dose injection of two targeted drugs (pertuzumab and trastuzumab) can eliminate all signs of HER2-positive breast cancer before surgery. About 112 adults with early-stage HER2+ breast cancer will receive this combination before their operation. The main goal is to see if the cancer completely disappears in the breast and lymph nodes at the time of surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCERS

Contacts and locations

Locations

Cancer Hospital of Shantou University Medical College
NOT_YET_RECRUITING

Shantou, Guangdong, China
Guangdong Women and children Hospital
NOT_YET_RECRUITING

Guangzhou, Guangdong, China
Guangxi Provincial Cancer Hospital
NOT_YET_RECRUITING

Nanning, Guangxi, China
Hainan Central Hospital
NOT_YET_RECRUITING

Haikou, Hainan, China
Peking University Cancer Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, China
Peking University Shenzhen Hospita
NOT_YET_RECRUITING

Shenzhen, China
Sun Yat-sen Memorial Hospital
RECRUITING

Guangzhou, Guangdong, China
The Affiliated Hospital of Guizhou Medical University
NOT_YET_RECRUITING

Guiyang, Guizhou, China
the First Affiliated Hospital of Wenzhou Medical University
NOT_YET_RECRUITING

Wenzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.